OPTIDART Trademark

Trademark Overview

On Friday, May 17, 2019, a trademark application was filed for OPTIDART with the United States Patent and Trademark Office. The USPTO has given the OPTIDART trademark a serial number of 79264896. The federal status of this trademark filing is REGISTERED as of Tuesday, December 28, 2021. This trademark is owned by Genexine, Inc.. The OPTIDART trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; vaccines; adjuvants for use with vaccines; vaccine preparations; anti-inflammatories; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; nucleic acid sequences for medical and veterinary purposes; diagnostic preparations for medical purposes for detecting mutation in prion genes; chemical preparations for use in DNA analysis for medical purposes; reagents for use in medical genetic testing; human vaccine preparations; pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; anti-asthmatic agents, namely, pharmaceutical preparations for the treatment of asthmatic disorders; dermatological pharmaceutical products; antibiotic preparations;...
optidart

General Information

Serial Number79264896
Word MarkOPTIDART
Filing DateFriday, May 17, 2019
Status700 - REGISTERED
Status DateTuesday, December 28, 2021
Registration Number6599482
Registration DateTuesday, December 28, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 12, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; vaccines; adjuvants for use with vaccines; vaccine preparations; anti-inflammatories; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; nucleic acid sequences for medical and veterinary purposes; diagnostic preparations for medical purposes for detecting mutation in prion genes; chemical preparations for use in DNA analysis for medical purposes; reagents for use in medical genetic testing; human vaccine preparations; pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; anti-asthmatic agents, namely, pharmaceutical preparations for the treatment of asthmatic disorders; dermatological pharmaceutical products; antibiotic preparations; biological preparations, namely, antibody fusion proteins for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 20, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGenexine, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressKR
Party NameGenexine, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressKR
Party NameGenexine, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events

Event DateEvent Description
Tuesday, July 5, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, June 10, 2022FINAL DISPOSITION NOTICE SENT TO IB
Thursday, June 9, 2022FINAL DISPOSITION PROCESSED
Monday, March 28, 2022FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, December 28, 2021REGISTERED-PRINCIPAL REGISTER
Sunday, October 24, 2021NOTIFICATION PROCESSED BY IB
Tuesday, October 12, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 12, 2021PUBLISHED FOR OPPOSITION
Wednesday, September 22, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 22, 2021NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, September 22, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, September 6, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, August 26, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 26, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, July 14, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, July 14, 2021NON-FINAL ACTION E-MAILED
Wednesday, July 14, 2021NON-FINAL ACTION WRITTEN
Wednesday, May 26, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 25, 2021ASSIGNED TO LIE
Wednesday, May 19, 2021TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Saturday, January 30, 2021NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, January 13, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, January 13, 2021NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Thursday, November 12, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, November 12, 2020ASSIGNED TO LIE
Thursday, May 28, 2020NEW REPRESENTATIVE AT IB RECEIVED
Wednesday, April 1, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, April 1, 2020LETTER OF SUSPENSION E-MAILED
Wednesday, April 1, 2020SUSPENSION LETTER WRITTEN
Saturday, March 7, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, March 7, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, March 7, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, September 28, 2019REFUSAL PROCESSED BY IB
Wednesday, September 11, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, September 11, 2019REFUSAL PROCESSED BY MPU
Tuesday, August 27, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, August 26, 2019NON-FINAL ACTION WRITTEN
Saturday, August 24, 2019APPLICATION FILING RECEIPT MAILED
Tuesday, August 20, 2019ASSIGNED TO EXAMINER
Tuesday, August 20, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 8, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

optidart preparations pharmaceutical treatment medical diseases purposes anti vaccine asthmatic disorders